Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jalava, SE"'
Autor:
Waltering, KK, Porkka, KP, Jalava, SE, Urbanucci, A, Kohonen, PJ, Latonen, LM, Kallioniemi, OP, Jenster, Guido, Visakorpi, T
Publikováno v:
Waltering, K K, Porkka, K P, Jalava, S E, Urbanucci, A, Kohonen, P J, Latonen, L M, Kallioniemi, O P, Jenster, G & Visakorpi, T 2011, ' Androgen regulation of micro-RNAs in prostate cancer ', The Prostate, vol. 71, no. 6, pp. 604-614 . https://doi.org/10.1002/pros.21276
Prostate, 71(6), 604-614. Wiley-Liss Inc.
Prostate, 71(6), 604-614. Wiley-Liss Inc.
BACKGROUND. Androgens play a critical role in the growth of both androgen dependent and castration-resistant prostate cancer (CRPC). Only a few micro-RNAs (miRNAs) have been suggested to be androgen regulated. We aim to identify androgen regulated mi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::537ebb2e6783404ddc3b6c3c4f33e614
Autor:
Puumalainen E; Faculty of Pharmacy, University of Helsinki, Helsinki, Finland. emmi.puumalainen@helsinki.fi., Airaksinen M; Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Jalava SE; Faculty of Pharmacy, University of Helsinki, Helsinki, Finland., Chen TF; Faculty of Medicine and Health, University of Sydney, Sydney, Australia., Dimitrow M; Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
Publikováno v:
European journal of clinical pharmacology [Eur J Clin Pharmacol] 2020 Mar; Vol. 76 (3), pp. 337-348. Date of Electronic Publication: 2019 Dec 10.
Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer.
Autor:
Jalava SE; Institute of Biomedical Technology, Tampere University, Tampere, Finland., Urbanucci A, Latonen L, Waltering KK, Sahu B, Jänne OA, Seppälä J, Lähdesmäki H, Tammela TL, Visakorpi T
Publikováno v:
Oncogene [Oncogene] 2012 Oct 11; Vol. 31 (41), pp. 4460-71. Date of Electronic Publication: 2012 Jan 23.
Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer.
Autor:
Martens-Uzunova ES; Department of Urology, Josephine Nefkens Institute, Erasmus MC, Rotterdam, The Netherlands., Jalava SE, Dits NF, van Leenders GJ, Møller S, Trapman J, Bangma CH, Litman T, Visakorpi T, Jenster G
Publikováno v:
Oncogene [Oncogene] 2012 Feb 23; Vol. 31 (8), pp. 978-91. Date of Electronic Publication: 2011 Jul 18.
Autor:
Waltering KK; Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland., Porkka KP, Jalava SE, Urbanucci A, Kohonen PJ, Latonen LM, Kallioniemi OP, Jenster G, Visakorpi T
Publikováno v:
The Prostate [Prostate] 2011 May; Vol. 71 (6), pp. 604-14. Date of Electronic Publication: 2010 Oct 13.
Autor:
Pittman AM; Section of Cancer Genetics, Institute of Cancer Research, Sutton, UK., Naranjo S, Jalava SE, Twiss P, Ma Y, Olver B, Lloyd A, Vijayakrishnan J, Qureshi M, Broderick P, van Wezel T, Morreau H, Tuupanen S, Aaltonen LA, Alonso ME, Manzanares M, Gavilán A, Visakorpi T, Gómez-Skarmeta JL, Houlston RS
Publikováno v:
PLoS genetics [PLoS Genet] 2010 Sep 16; Vol. 6 (9), pp. e1001126. Date of Electronic Publication: 2010 Sep 16.
Autor:
Rauhala HE; Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland., Jalava SE, Isotalo J, Bracken H, Lehmusvaara S, Tammela TL, Oja H, Visakorpi T
Publikováno v:
International journal of cancer [Int J Cancer] 2010 Sep 01; Vol. 127 (6), pp. 1363-72.
Autor:
Jalava SE; Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland., Porkka KP, Rauhala HE, Isotalo J, Tammela TL, Visakorpi T
Publikováno v:
International journal of cancer [Int J Cancer] 2009 Jan 01; Vol. 124 (1), pp. 95-102.